Sangui Biotech International, Inc. Stock OTC Markets
Equities
SGBI
US80105B1017
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0015 USD | +25.00% | -.--% | -48.28% |
Sales 2021 | 65.58K 89.42K | Sales 2022 | 69.19K 94.34K | Capitalization | 3.09M 4.21M |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | 90.6 x |
Net Debt 2021 | 790K 1.08M | Net Debt 2022 | 795K 1.08M | EV / Sales 2022 | 56.1 x |
P/E ratio 2021 |
-25.6
x | P/E ratio 2022 |
-51.8
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 86.94% |
1 day | +25.00% | ||
6 months | -48.28% | ||
Current year | -48.28% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Striepe
CEO | Chief Executive Officer | 62 | 05-02-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Striepe
CEO | Chief Executive Officer | 62 | 05-02-06 |
Hubertus Schmelz
BRD | Director/Board Member | 68 | 08-12-17 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
-10.62% | 37.68B | |
+40.49% | 39.84B | |
+29.92% | 31.46B | |
-9.78% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- SBH Stock
- SGBI Stock